Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.77 |
| ▸ | MMP10 | P09238 | 3/20 | 0.70 |
| ▸ | MMP8 | P22894 | 3/20 | 0.70 |
| ▸ | MMP9 | P14780 | 1/20 | 0.70 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717299 | 0.90 | MMP13 (0.73) | MMP13MMP10MMP8MMP9NR1H4 | |
| SCHEMBL15647278 | 0.89 | MMP13 (0.86) | MMP13MMP10MMP8MMP9NR1H4 | |
| SCHEMBL5616139 | 0.88 | MMP13 (0.78) | MMP13MMP10MMP8MMP9ALDH1A1 | |
| SCHEMBL5616136 | 0.88 | MMP13 (0.78) | MMP13MMP10MMP8MMP9NR1H4 | |
| SCHEMBL5615881 | 0.88 | MMP13 (0.82) | MMP13MMP10MMP8MMP9HDAC1 | |
| SCHEMBL8358823 | 0.88 | MMP13 (1.00) | MMP13MMP10MMP8MMP9HDAC1 | |
| SCHEMBL29838134 | 0.88 | MMP13 (1.00) | MMP13MMP10MMP8MMP9HDAC1 | |
| SCHEMBL5615671 | 0.87 | MMP13 (0.84) | MMP13MMP10MMP8MMP9NR1H4 | |
| SCHEMBL8360162 | 0.87 | MMP13 (0.88) | MMP13MMP10MMP8MMP9ALDH1A1 | |
| SCHEMBL8357428 | 0.85 | MMP13 (0.90) | MMP13MMP10MMP8MMP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | claimed |
| EP-1560815-A1 | NOVEL PYRIMIDINE-4,6-DICARBOXAMIDES FOR THE SELECTIVE INHIBITION OF COLLAGENASES | Aventis Pharma Deutschland GmbH (DE) | 2005-08-10 | — | — | EP | claimed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | claimed |
| WO-2004041788-A1 | NOVEL PYRIMIDINE-4,6-DICARBOXAMIDES FOR THE SELECTIVE INHIBITION OF COLLAGENASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-21 | — | — | WO | claimed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| EP-1560815-A1 | NOVEL PYRIMIDINE-4,6-DICARBOXAMIDES FOR THE SELECTIVE INHIBITION OF COLLAGENASES | Aventis Pharma Deutschland GmbH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | disclosed |
| WO-2004041788-A1 | NOVEL PYRIMIDINE-4,6-DICARBOXAMIDES FOR THE SELECTIVE INHIBITION OF COLLAGENASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | MMP13, DPYD, MMP1 | MMP13 1/4885MMP10 15/4885MMP8 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.